Inflammation, Rezolved.
Better tomorrows start with reducing chronic inflammation today.
We are focused on reducing chronic inflammation at the source to improve lives.
We have spent over a decade inventing and developing molecules that block the activity of inflammation where it matters – in the blood vessels, in the heart, and in the brain to change the lives of people living with cardiovascular and neurologic diseases. Our company’s primary focus is inhibiting NLRP3, an upstream ‘switch’ that drives chronic inflammation, without impacting the body’s ability to fight infection.
Our Programs
We aim to reduce chronic inflammation at an early stage of disease, when we have the potential to make a positive long-term impact for people with inflammation-driven cardiovascular and neurologic disease.


Our Clinical Trials
We believe NLRP3 activity is a major driver of disease severity and progression for hundreds of millions of people living with peripheral artery disease (PAD) worldwide. We plan to initiate a registrational Phase 3 clinical trial in the first half of 2027 to study ruvonoflast in people living with PAD.
Recent Press Releases
Rezera News
Rezera Announces Positive RESOLVE-2 Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile for Ruvonoflast in Combination with Semaglutide
Read
Rezera News
Rezera Announces Phase 1 Results for Trabzanoflast, which was Generally Well Tolerated and Demonstrated High Central Nervous System Exposure (CNS)
Read
Rezera News
Rezera Announces Late-Breaking Presentation of RESOLVE-1 Clinical Data at the American Heart Association (AHA) Scientific Sessions 2026
Read